EP3877418A4 - ANTI-TIGIT ANTIBODY DOSAGE REGIMEN FOR THE TREATMENT OF CANCER - Google Patents
ANTI-TIGIT ANTIBODY DOSAGE REGIMEN FOR THE TREATMENT OF CANCER Download PDFInfo
- Publication number
- EP3877418A4 EP3877418A4 EP19881474.1A EP19881474A EP3877418A4 EP 3877418 A4 EP3877418 A4 EP 3877418A4 EP 19881474 A EP19881474 A EP 19881474A EP 3877418 A4 EP3877418 A4 EP 3877418A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- treatment
- dosing regimen
- tigit antibody
- tigit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862755805P | 2018-11-05 | 2018-11-05 | |
PCT/US2019/059581 WO2020096915A1 (en) | 2018-11-05 | 2019-11-04 | Dosing regimen of anti-tigit antibody for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3877418A1 EP3877418A1 (en) | 2021-09-15 |
EP3877418A4 true EP3877418A4 (en) | 2022-08-17 |
Family
ID=70611082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19881474.1A Pending EP3877418A4 (en) | 2018-11-05 | 2019-11-04 | ANTI-TIGIT ANTIBODY DOSAGE REGIMEN FOR THE TREATMENT OF CANCER |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210403557A1 (ko) |
EP (1) | EP3877418A4 (ko) |
JP (1) | JP2022512851A (ko) |
KR (1) | KR20210091209A (ko) |
CN (1) | CN113302204A (ko) |
AU (1) | AU2019375409A1 (ko) |
BR (1) | BR112021008582A8 (ko) |
CA (1) | CA3118964A1 (ko) |
MX (1) | MX2021005236A (ko) |
WO (1) | WO2020096915A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2279412T3 (pl) | 2008-04-09 | 2017-12-29 | Genentech, Inc. | Nowe kompozycje i sposoby leczenia chorób o podłożu immunologicznym |
KR20230024368A (ko) * | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
EP4219553A1 (en) * | 2020-09-22 | 2023-08-02 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-tigit antibody and double antibody and their application |
WO2023018675A1 (en) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
WO2023018677A1 (en) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | A therapeutic combination comprising a t1git antagonist, a pd-1 antagonist, and a chemotherapeutic agent(s) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016028656A1 (en) * | 2014-08-19 | 2016-02-25 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
WO2016168716A1 (en) * | 2015-04-17 | 2016-10-20 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014149425A1 (en) * | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
-
2019
- 2019-11-04 US US17/288,641 patent/US20210403557A1/en active Pending
- 2019-11-04 AU AU2019375409A patent/AU2019375409A1/en active Pending
- 2019-11-04 JP JP2021523335A patent/JP2022512851A/ja active Pending
- 2019-11-04 EP EP19881474.1A patent/EP3877418A4/en active Pending
- 2019-11-04 WO PCT/US2019/059581 patent/WO2020096915A1/en unknown
- 2019-11-04 KR KR1020217017162A patent/KR20210091209A/ko unknown
- 2019-11-04 BR BR112021008582A patent/BR112021008582A8/pt unknown
- 2019-11-04 CA CA3118964A patent/CA3118964A1/en active Pending
- 2019-11-04 MX MX2021005236A patent/MX2021005236A/es unknown
- 2019-11-04 CN CN201980087763.5A patent/CN113302204A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016028656A1 (en) * | 2014-08-19 | 2016-02-25 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
WO2016168716A1 (en) * | 2015-04-17 | 2016-10-20 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
Non-Patent Citations (1)
Title |
---|
See also references of WO2020096915A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020096915A1 (en) | 2020-05-14 |
JP2022512851A (ja) | 2022-02-07 |
BR112021008582A8 (pt) | 2023-02-07 |
CA3118964A1 (en) | 2020-05-14 |
EP3877418A1 (en) | 2021-09-15 |
CN113302204A (zh) | 2021-08-24 |
MX2021005236A (es) | 2021-06-18 |
BR112021008582A2 (pt) | 2021-08-10 |
US20210403557A1 (en) | 2021-12-30 |
AU2019375409A1 (en) | 2021-05-27 |
KR20210091209A (ko) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3244926A4 (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
EP3565844B8 (en) | Methods of treating cancer with anti-pd-1 antibodies | |
EP3341413A4 (en) | MONOCLONAL ANTI-DESPR ANTIBODY-TARGETED TREATMENT AND IMAGING FOR CANCER AND AVC | |
EP3877418A4 (en) | ANTI-TIGIT ANTIBODY DOSAGE REGIMEN FOR THE TREATMENT OF CANCER | |
EP3494142A4 (en) | ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER | |
IL268479A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
EP3752180A4 (en) | METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES | |
EP3806871A4 (en) | SINGLE-CHAIN BISPECIFIC CHEMICAL ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | |
EP3645040A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS | |
IL277861A (en) | Axl-specific antibodies for cancer treatment | |
EP3383497A4 (en) | NEW ANTIBODIES FOR THE TREATMENT OF CANCERS | |
IL274766A (en) | Human anti-LIV1 antibodies for the treatment of breast cancer | |
EP3842071A4 (en) | USE OF TIM-3 ANTIBODIES IN THE MANUFACTURE OF PHARMACEUTICALS FOR THE TREATMENT OF TUMORS | |
EP3432925A4 (en) | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY | |
EP3502142A4 (en) | BISPECIFIC ANTIBODY AND ANTIBODY CONJUGATE FOR TUMOR THERAPY AND USE THEREOF | |
IL265762A (en) | Dosing regimen of avolumab for cancer treatment | |
EP3289084A4 (en) | siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER | |
IL268460A (en) | Treatment of bladder cancer with an antibody against pd-l1 | |
EP3880709A4 (en) | ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR THE TREATMENT OF CANCER | |
EP3877420A4 (en) | HER2-S310F-SPECIFIC ANTIGEN BINDING MOLECULE | |
EP3735423A4 (en) | NEO-201 MONOCLONAL ANTIBODY FOR TREATMENT OF HUMAN CARCINOMA | |
IL291432A (en) | Dosage for anti-tryptase antibodies | |
IL280421A (en) | Cancer treatment by antibody | |
EP4051712A4 (en) | DOSAGE SCHEME OF ANTI-CD27 ANTIBODIES FOR THE TREATMENT OF CANCER | |
EP3344287A4 (en) | ANTI-SURVIVIN ANTIBODIES FOR THE TREATMENT OF CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210607 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220718 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101ALI20220712BHEP Ipc: C07K 16/28 20060101AFI20220712BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK SHARP & DOHME LLC |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230816 |